Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 04 2023 - 7:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
December 2023
Commission File Number: 001-38723
Tiziana Life Sciences LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107
Cheapside
London
EC2V
6DN
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On December 4, 2023, Tiziana Life Sciences LTD (the
“Company”) issued this 6K announcing, that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present
at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation
will be focused on Tiziana’s recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal
antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other neuroinflammatory and neurodegenerative
diseases such as Alzheimer’s disease, a copy of which is furnished as Exhibit 99.1
The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES LTD |
|
|
|
|
|
|
|
|
Date: December 4, 2023 |
By: |
/s/ Keeren Shah |
|
|
Name: |
Keeren Shah |
|
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
Exhibit 99.1
![Primary Logo](https://www.sec.gov/Archives/edgar/data/1723069/000121390023092323/image_001.jpg)
Tiziana
Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
NEW YORK, December 4, 2023 -- Tiziana
Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing
breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer
and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December
6th at 3:00 PM ET. The presentation will be focused on Tiziana’s recent clinical updates and our Phase 2 trial of intranasal foralumab,
a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other
neuroinflammatory and neurodegenerative diseases such as Alzheimer’s disease.
Conference Details:
Conference: Webull LIVE! with Corporate
Connect: Biotech Investment Webinar
Date/Time: Wednesday, December 6th at
3:00 PM ET
Presenter: Matthew Davis, Chief Operating
Officer & Chief Medical Officer
Registration Link: https://us02web.zoom.us/webinar/register/WN_9-kFpy_DQ8OlBAoDQg8D7w
About Foralumab
Activated T cells play an
important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor
and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect
has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal
foralumab Phase 2 trial is ongoing in patients with non-active SPMS. Immunomodulation
by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.1,2
About Tiziana
Life Sciences
Tiziana
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has
the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.
Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety
profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has
been patented with several applications pending and is expected to allow for broad pipeline applications.
About
Webull Financial
Webull
is a leading digital investment platform built on next generation global infrastructure. The Webull Group serves tens of millions of
users from over 180 countries, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies
to work by trading global stocks, ETFs, options and fractional shares, through Webull’s trading platform, which is currently available
in the United States, the United Kingdom, Hong Kong, Singapore, Japan, South Africa, and Australia. Webull also offers investment education
services, with lessons covering a wide range of topics.
References:
1 https://www.pnas.org/doi/10.1073/pnas.2220272120
2 https://www.pnas.org/doi/10.1073/pnas.2309221120
For
further inquiries:
Tiziana
Life Sciences Ltd
Paul Spencer,
Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
+1 646 970 4681
ikoffler@lifesciadvisors.com
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Aug 2023 to Aug 2024